Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Axicabtagene Ciloleucel & Folicular Lymphoma, in March 2021, the FDA granted accelerated approval to axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma after at least two prior lines of systemic therapy (1). The approval was based on the phase II ZUMA‑5 trial in indolent NHL, including FL, showing an objective response rate around 90% and high complete response rates in heavily pre‑treated patients (1, 2, 3).
Axicabtagene ciloleucel is authorized in the EU for relapsed/refrac…